Please ensure Javascript is enabled for purposes of website accessibility

How Pfizer Beat Q2 Estimates Despite Upjohn Sales Plunging 31%

By Keith Speights - Jul 28, 2020 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Several of the big drugmaker's blockbuster drugs performed well in the second quarter.

Pfizer (PFE -3.32%) has had a very eventful year so far in 2020. The COVID-19 pandemic interfered with the timing of the company's planned merger of Upjohn with Mylan. It also prompted Pfizer to team up with German biotech BioNTech on the development of a COVID-19 vaccine candidate. Pfizer has also reported both good and bad news with its pipeline candidates over the last several months.

Now there's another event to add to Pfizer's eventful year: The company announced its second-quarter results before the market opened on Tuesday. Here are the highlights from Pfizer's Q2 update.

Dollar sign formed in pills.

Image source: Getty Images.

By the numbers

Pfizer reported revenue of $11.8 billion in the second quarter, down 11% year over year. Despite the decline, the result beat the average analysts' estimate of $11.55 billion.

The company reported Q2 net income of $3.4 billion, or $0.61 per share, based on generally accepted accounting principles (GAAP). This reflected a steep drop from Pfizer's GAAP earnings of $5 billion, or $0.89 per share, in the prior-year period. 

Pfizer recorded adjusted net income in the second quarter of $4.4 billion, or $0.78 per share. This was slightly below the company's adjusted net income of $4.5 billion, or $0.80 per share, posted in the same quarter of 2019. However, it handily topped the consensus analysts' adjusted earnings estimate of $0.66 per share.

Behind the numbers

The revenue and earnings declines for Pfizer in the second quarter are somewhat deceiving. Pfizer spun off its consumer healthcare business into a joint venture with GlaxoSmithKline last year. Excluding the impact of this transaction and foreign exchange headwinds, Pfizer's revenue slipped by only 3% year over year in Q2.

Upjohn continued to be the main problem area. Revenue for the segment plunged 31% year over year in Q2 to $2 billion. Most of this drop stemmed from a steep decline in sales for Lyrica, which began to face generic competition in the U.S. in July 2019. Excluding the impact of the falling sales of Lyrica, Upjohn's Q2 revenue declined by 6% year over year on a constant-currency basis.

The COVID-19 pandemic also took a toll. Pfizer stated that its Q2 revenue was around $500 million lower -- roughly 4% lower overall -- because of disruptions to physician visits and lower demand for some products in China due to the pandemic.

There was plenty of good news for Pfizer in Q2, though. Biopharma segment revenue jumped 6% year over year to $9.8 billion. Sales of rare-disease drugs Vyndaqel and Vyndamax totaled $277 million, with 140% operational growth in international markets. Blood thinner Eliquis delivered 19% operational sales growth.

Looking ahead

Pfizer raised its full-year 2020 guidance. It now projects revenue between $48.6 billion and $50.6 billion, up from its previous forecast of a range of $40.7 billion to $42.3 billion. The company expects non-GAAP EPS will be between $2.85 and $2.95, up from its previous guidance of $2.25 to $2.35.

The pharma stock should have several key catalysts on the way. The Upjohn-Mylan merger is expected to close in the fourth quarter of this year. Pfizer and BioNTech advanced a COVID-19 vaccine candidate into late-stage testing this week. If all goes well in this study, the companies hope to seek regulatory approval for the vaccine as early as October 2020.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$48.29 (-3.32%) $-1.66
Viatris Inc. Stock Quote
Viatris Inc.
GSK Stock Quote
$35.73 (-6.71%) $-2.57
BioNTech SE Stock Quote
BioNTech SE
$158.59 (-1.45%) $-2.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.